Recent insights into the pathogenesis and therapeutics of pulmonary hypertension

被引:25
作者
Strange, JW [1 ]
Wharton, J [1 ]
Phillips, PG [1 ]
Wilkins, MR [1 ]
机构
[1] Hammersmith Hosp, Imperial Coll, Clin Pharmacol Sect, London W12 0NN, England
关键词
BMP type II receptor; genetic predisposition; hypoxia; pulmonary hypertension; therapeutics; transforming growth; factor beta receptor;
D O I
10.1042/CS20010212
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The normal adult pulmonary circulation is a low-pressure, high-capacity circuit. Pulmonary vascular resistance is regulated by alveolar oxygen tension, potassium channels and a variety of locally produced and circulating vasoactive factors. Perturbations of these systems may contribute to the pathogenesis of pulmonary hypertension. Recently, mutations in BMPR2 and ALK-1, genes that encode members of the transforming growth factor-beta (TGF-beta) receptor superfamily, have been found in patients with primary pulmonary hypertension. These observations provide a novel insight into the pathogenesis of primary pulmonary hypertension, and emphasize the importance of the integrity of the TGF-beta receptor family in the maintenance of normal pulmonary vascular structure and function. This review discusses the latest developments in the field of pulmonary vascular biology and the prospects for improving the treatment of pulmonary hypertension.
引用
收藏
页码:253 / 268
页数:16
相关论文
共 156 条
[21]  
Champion HC, 1999, CIRC RES, V84, P1422
[22]   In vivo gene transfer of prepro-calcitonin gene-related peptide to the lung attenuates chronic hypoxia-induced pulmonary hypertension in the mouse [J].
Champion, HC ;
Bivalacqua, TJ ;
Toyoda, K ;
Heistad, DD ;
Hyman, AL ;
Kadowitz, PJ .
CIRCULATION, 2000, 101 (08) :923-930
[23]   Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension - An ambulatory delivery system and initial clinical tests [J].
Channick, RN ;
Newhart, JW ;
Johnson, FW ;
Williams, PJ ;
Auger, WR ;
Fedullo, PF ;
Moser, KM .
CHEST, 1996, 109 (06) :1545-1549
[24]   Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study [J].
Channick, RN ;
Simonneau, G ;
Sitbon, O ;
Robbins, IM ;
Frost, A ;
Tapson, VF ;
Badesch, DB ;
Roux, S ;
Rainisio, M ;
Bodin, F ;
Rubin, LJ .
LANCET, 2001, 358 (9288) :1119-1123
[25]  
CHAZOVA I, 1995, AM J PATHOL, V146, P389
[26]   Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats [J].
Chen, SJ ;
Chen, YF ;
Meng, QC ;
Durand, J ;
Dicarlo, VS ;
Oparil, S .
JOURNAL OF APPLIED PHYSIOLOGY, 1995, 79 (06) :2122-2131
[27]   Characterization of new mutations in the coding sequence and 5'-untranslated region of the human prostacyclin synthase gene (CYP8A1) [J].
Chevalier, D ;
Cauffiez, C ;
Bernard, C ;
Lo-Guidice, JM ;
Allorge, D ;
Fazio, F ;
Ferrari, N ;
Libersa, C ;
Lhermitte, M ;
D'Halluin, JC ;
Broly, F .
HUMAN GENETICS, 2001, 108 (02) :148-155
[28]   AN IMBALANCE BETWEEN THE EXCRETION OF THROMBOXANE AND PROSTACYCLIN METABOLITES IN PULMONARY-HYPERTENSION [J].
CHRISTMAN, BW ;
MCPHERSON, CD ;
NEWMAN, JH ;
KING, GA ;
BERNARD, GR ;
GROVES, BM ;
LOYD, JE .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (02) :70-75
[29]   Inhibition of cyclic 3'-5'-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats [J].
Cohen, AH ;
Hanson, K ;
Morris, K ;
Fouty, B ;
McMurtry, IF ;
Clarke, W ;
Rodman, DM .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (01) :172-179
[30]  
Conti M, 2000, PROG NUCLEIC ACID RE, V63, P1